PF-Atlas › Treatments › CAR-T Anti-FAP Fibroblasts
CAR-T Anti-FAP Fibroblasts
Direct clearance of FAP+ activated myofibroblasts via chimeric antigen receptor T cells
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Preclinical
Evidence level
Level 2 (Preclinical)
Mechanism class
Direct clearance of FAP+ activated myofibroblasts via chimeric antigen receptor T cells
Timeline
4-6 years
Risk profile
Medium-High
Developer
Penn / Multiple
Key researchers
J. Epstein
Overview
Nature 2022: FAP-CAR-T cleared cardiac fibrosis in mice. Lung fibrosis has same FAP+ myofibroblast target. Cross-reactive FAP scFv-based CAR-T evaluated for efficacy/safety 2024. Cancer crossover: same CAR design eliminates cancer-associated fibroblasts.
How CAR-T Anti-FAP Fibroblasts fits into IPF treatment
CAR-T Anti-FAP Fibroblasts is classified as Level 2 (Preclinical) at the Preclinical stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about CAR-T Anti-FAP Fibroblasts for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.